12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Nontoxic concentration of DNA‐PK inhibitor NU7441 radio‐sensitizes lung tumor cells with little effect on double strand break repair

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          High‐linear energy transfer ( LET) heavy ions have been increasingly employed as a useful alternative to conventional photon radiotherapy. As recent studies suggested that high LET radiation mainly affects the nonhomologous end‐joining ( NHEJ) pathway of DNA double strand break ( DSB) repair, we further investigated this concept by evaluating the combined effect of an NHEJ inhibitor ( NU7441) at a non‐toxic concentration and carbon ions. NU7441‐treated non‐small cell lung cancer ( NSCLC) A549 and H1299 cells were irradiated with X‐rays and carbon ions (290 MeV/n, 50 keV/μm). Cell survival was measured by clonogenic assay. DNA DSB repair, cell cycle distribution, DNA fragmentation and cellular senescence induction were studied using a flow cytometer. Senescence‐associated protein p21 was detected by western blotting. In the present study, 0.3 μM of NU7441, nontoxic to both normal and tumor cells, caused a significant radio‐sensitization in tumor cells exposed to X‐rays and carbon ions. This concentration did not seem to cause inhibition of DNA DSB repair but induced a significant G2/M arrest, which was particularly emphasized in p53‐null H1299 cells treated with NU7441 and carbon ions. In addition, the combined treatment induced more DNA fragmentation and a higher degree of senescence in H1299 cells than in A549 cells, indicating that DNAPK inhibitor contributes to various modes of cell death in a p53‐dependent manner. In summary, NSCLC cells irradiated with carbon ions were radio‐sensitized by a low concentration of DNAPK inhibitor NU7441 through a strong G2/M cell cycle arrest. Our findings may contribute to further effective radiotherapy using heavy ions.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          Senescence and aging: the critical roles of p53.

          p53 functions as a transcription factor involved in cell-cycle control, DNA repair, apoptosis and cellular stress responses. However, besides inducing cell growth arrest and apoptosis, p53 activation also modulates cellular senescence and organismal aging. Senescence is an irreversible cell-cycle arrest that has a crucial role both in aging and as a robust physiological antitumor response, which counteracts oncogenic insults. Therefore, via the regulation of senescence, p53 contributes to tumor growth suppression, in a manner strictly dependent by its expression and cellular context. In this review, we focus on the recent advances on the contribution of p53 to cellular senescence and its implication for cancer therapy, and we will discuss p53's impact on animal lifespan. Moreover, we describe p53-mediated regulation of several physiological pathways that could mediate its role in both senescence and aging.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

            Here we report a comprehensive biological characterization of a potent and selective small-molecule inhibitor of the DNA damage response (DDR) kinase ATR. We show a profound synthetic lethal interaction between ATR and the ATM-p53 tumor suppressor pathway in cells treated with DNA-damaging agents and establish ATR inhibition as a way to transform the outcome for patients with cancer treated with ionizing radiation or genotoxic drugs.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience.

              Charged particle therapy is generally regarded as cutting-edge technology in oncology. Many proton therapy centres are active in the USA, Europe, and Asia, but only a few centres use heavy ions, even though these ions are much more effective than x-rays owing to the special radiobiological properties of densely ionising radiation. The National Institute of Radiological Sciences (NIRS) Chiba, Japan, has been treating cancer with high-energy carbon ions since 1994. So far, more than 8000 patients have had this treatment at NIRS, and the centre thus has by far the greatest experience in carbon ion treatment worldwide. A panel of radiation oncologists, radiobiologists, and medical physicists from the USA and Europe recently completed peer review of the carbon ion therapy at NIRS. The review panel had access to the latest developments in treatment planning and beam delivery and to all updated clinical data produced at NIRS. A detailed comparison with the most advanced results obtained with x-rays or protons in Europe and the USA was then possible. In addition to those tumours for which carbon ions are known to produce excellent results, such as bone and soft-tissue sarcoma of the skull base, head and neck, and pelvis, promising data were obtained for other tumours, such as locally recurrent rectal cancer and pancreatic cancer. The most serious impediment to the worldwide spread of heavy ion therapy centres is the high initial capital cost. The 20 years of clinical experience at NIRS can help guide strategic decisions on the design and construction of new heavy ion therapy centres. Copyright © 2015 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                rokayasu@nirs.go.jp
                Journal
                Cancer Sci
                Cancer Sci
                10.1111/(ISSN)1349-7006
                CAS
                Cancer Science
                John Wiley and Sons Inc. (Hoboken )
                1347-9032
                1349-7006
                01 September 2016
                September 2016
                : 107
                : 9 ( doiID: 10.1111/cas.2016.107.issue-9 )
                : 1250-1255
                Affiliations
                [ 1 ] Department of Nuclear Engineering and Management School of EngineeringUniversity of Tokyo TokyoJapan
                [ 2 ] Research Center for Radiation ProtectionNational Institute of Radiological Sciences ChibaJapan
                [ 3 ] Research Center for Radiation Emergency MedicineNational Institute of Radiological Sciences ChibaJapan
                Author notes
                [*] [* ] Correspondence

                Ryuichi Okayasu, Research Center for Radiation Protection, National Institute of Radiological Sciences, 4‐9‐1 Anagawa, Inage‐ku, Chiba 263‐8555, Japan.

                Tel: +81‐43‐382‐3711; Fax: +81‐43‐255‐0720;

                E‐mail: rokayasu@ 123456nirs.go.jp

                Article
                CAS12998
                10.1111/cas.12998
                5021029
                27341700
                2f96fc40-7d2d-481c-a30f-746ac7e49303
                © 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

                This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 05 April 2016
                : 21 June 2016
                : 23 June 2016
                Page count
                Figures: 5, Tables: 0, Pages: 6, Words: 4419
                Funding
                Funded by: Japan Society for the Promotion of Science
                Award ID: 15J09331
                Award ID: 24249067
                Categories
                Original Article
                Original Articles
                Cell, Molecular, and Stem Cell Biology
                Custom metadata
                2.0
                cas12998
                September 2016
                Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:13.09.2016

                Oncology & Radiotherapy
                dnapk protein,g2 cell cycle arrest,heavy ions,non‐small cell lung cancer,p53 genes

                Comments

                Comment on this article